Actinium Pharmaceuticals

Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
Company Growth (employees)
Type
Public
HQ
New York, US
Founded
2000
Size (employees)
23 (est)+28%
Actinium Pharmaceuticals was founded in 2000 and is headquartered in New York, US

Actinium Pharmaceuticals Office Locations

Actinium Pharmaceuticals has an office in New York
New York, US (HQ)
275 Madison Ave

Actinium Pharmaceuticals Data and Metrics

Actinium Pharmaceuticals Financial Metrics

USD

Net income (Q1, 2017)

(8.1 m)

EBIT (Q1, 2017)

(7.8 m)

Market capitalization (17-Aug-2017)

34.9 m

Cash (31-Mar-2017)

17.1 m
Actinium Pharmaceuticals's current market capitalization is $34.9 m.
USDFY, 2014FY, 2016

R&D expense

12.3 m

General and administrative expense

10.2 m9.3 m

Operating expense total

22.5 m26.8 m

EBIT

(22.5 m)(26.8 m)

Interest expense

866(5 k)

Net Income

(24.7 m)(24.3 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

General and administrative expense

2.4 m3.3 m3.8 m3.6 m1.8 m2.2 m2.8 m1.4 m3.3 m

Operating expense total

2.4 m3.3 m3.8 m3.6 m1.8 m2.2 m2.8 m1.4 m3.3 m

EBIT

(4.4 m)(7 m)(7.9 m)(7.4 m)(4.6 m)(6 m)(6.9 m)(7.1 m)(7.8 m)

Interest expense

(5.7 k)(1.6 k)(588)(2.7 k)(1.7 k)(666)

Net Income

(13.2 m)(19.3 m)(3.1 m)(10.5 m)(14.5 m)(4.4 m)(11 m)(17.6 m)(8.1 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

5.5 m6.7 m25.6 m20.5 m

Accounts Receivable

2.1 b

Inventories

218.4 k699.9 k803.5 k1.8 m

Current Assets

5.8 m7.4 m26.5 m22.4 m

PP&E

13.9 k127.7 k106.1 k88.5 k

Total Assets

5.8 m7.6 m26.6 m22.5 m

Accounts Payable

379 k2.3 m1.5 m4.2 m

Total Debt

315.7 k567.1 k531.4 k

Current Liabilities

7.3 m9.5 m4.6 m4.5 m

Total Liabilities

4.5 m

Additional Paid-in Capital

64.9 m89.3 m134.2 m154.5 m

Retained Earnings

(91.2 m)(112.2 m)(136.6 m)

Total Equity

(1.6 m)(1.9 m)22 m18 m

Debt to Equity Ratio

-0.2 x-0.3 x0 x

Debt to Assets Ratio

0.1 x0.1 x0 x

Financial Leverage

-3.7 x-3.9 x1.2 x1.3 x
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

26 m24.8 m22.2 m20.5 m15.5 m17.1 m

Current Assets

26.2 m24.9 m23.2 m21.4 m17.1 m18.1 m

PP&E

86.2 k95.3 k115.6 k110 k91.2 k75.9 k

Total Assets

26.3 m25 m23.3 m21.6 m17.3 m18.2 m

Accounts Payable

1 m888.5 k1.9 m1.4 m2.6 m4.8 m

Current Liabilities

3.1 m2.2 m3.3 m2.5 m3 m5.4 m

Additional Paid-in Capital

125 m128.5 m136.6 m142.3 m144 m157.4 m

Retained Earnings

(101.7 m)(105.7 m)(116.6 m)(123.3 m)(129.9 m)(144.6 m)

Total Equity

23.3 m22.9 m20.1 m19.1 m14.2 m12.9 m

Financial Leverage

1.1 x1.1 x1.2 x1.1 x1.2 x1.4 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(10.8 m)(24.7 m)(21 m)(24.3 m)

Depreciation and Amortization

1.6 k37.9 k53.5 k77.5 k

Inventories

106.6 k(193.9 k)162.1 k(1 m)

Accounts Payable

(793.9 k)2.7 m

Cash From Operating Activities

(6.3 m)(14.3 m)(18.5 m)(20.8 m)

Purchases of PP&E

(16.6 k)(151.7 k)(47.8 k)(60 k)

Cash From Investing Activities

(16.6 k)(186.4 k)(47.8 k)(109.8 k)

Cash From Financing Activities

6.2 m15.7 m37.5 m15.8 m

Interest Paid

5618667.9 k5 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(13.2 m)(19.3 m)(3.1 m)(10.5 m)(14.5 m)(4.4 m)(11 m)(17.6 m)(8.1 m)

Depreciation and Amortization

9.5 k23.8 k10.4 k26.6 k43.4 k18.1 k37.6 k57.7 k20.9 k

Accounts Payable

666.5 k1.4 m(1 m)(1.3 m)(1.4 m)378.9 k(94.8 k)1.1 m573.9 k

Cash From Operating Activities

(5.1 m)(9.3 m)(5.8 m)(11.1 m)(14.6 m)(4.8 m)(11 m)(16.5 m)(5.4 m)

Purchases of PP&E

(128.4 k)(150.9 k)(959)(26.9 k)(27.6 k)(41.5 k)(42.7 k)(8.3 k)

Cash From Investing Activities

(128.4 k)(150.9 k)(959)(26.9 k)(77.4 k)(91.3 k)(92.6 k)26.4 k

Cash From Financing Activities

14.3 m15.7 m18.4 m30.3 m32.7 m1.4 m5.9 m6.5 m1.9 m

Interest Paid

5.7 k7.3 k7.9 k2.7 k4.3 k5 k
Y, 2017

Financial Leverage

1.4 x

Actinium Pharmaceuticals Market Value History

Traffic Overview of Actinium Pharmaceuticals

Actinium Pharmaceuticals Online and Social Media Presence

Actinium Pharmaceuticals Company Life and Culture

You may also be interested in